Matching articles for "Aucatzyl"
In Brief: Obecabtagene Autoleucel (Aucatzyl) - Another CAR-T Cell Immunotherapy for ALL (online only)
The Medical Letter on Drugs and Therapeutics • December 23, 2024; (Issue 1718)
Obecabtagene autoleucel (Aucatzyl – Autolus), a
CD19-directed genetically modified autologous T cell
immunotherapy, has been approved by the FDA for
treatment of relapsed or refractory B-cell...
Obecabtagene autoleucel (Aucatzyl – Autolus), a
CD19-directed genetically modified autologous T cell
immunotherapy, has been approved by the FDA for
treatment of relapsed or refractory B-cell precursor
acute lymphoblastic leukemia (ALL) in adults. The
CAR T-cell immunotherapy products tisagenlecleucel
(Kymriah) and brexucabtagene auto-leucel (Tecartus)
were approved earlier for the same indication.